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ABSTRACT
Bisphosphonates are recently acquiring increasing relevance in the treatment of several diseases.
In line with the increased use of these compounds, cases of mandibular osteonecrosis, and to a lesser extent, maxillary osteone-
crosis, are being reported. This necrosis is difficult to treat in patients who usually have a previously limited quality of life.
A surgical performance carried out by oral and maxillofacial surgeons, stomatologists and odontologists might lead to bone exposure.
A treatment based on conservation and as harmless as possible seems to be the most advisable way of acting with these patients 
in order to minimize the incidence and treat the complications, once the lesions have been ascertained.
We report three cases treated in our service of osteonecrosis of the jaws after exodontics.
This side effect should be remembered before starting any surgical treatment in these patients.
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RESUMEN
Los bisfosfonatos están adquiriendo una relevancia terapéutica cada vez mayor, dada su utilidad en el manejo de diversas patologías.
Con el incremento de su uso, se están documentando casos de necrosis ósea mandibular, y en menor medida maxilar, de difícil 
solución y con una importante afectación de la calidad de vida de los pacientes en tratamiento con estos fármacos.
El factor que con mayor frecuencia desencadena el proceso es la actuación de los profesionales: odontólogos, estomatólogos 
y cirujanos orales y maxilofaciales. 
La previsión, las intervenciones atraumáticas y el tratamiento conservador, parecen ser los medios más adecuados para mini-
mizar la incidencia o resolver las complicaciones.
Este artículo presenta tres casos, seguidos por nuestro servicio, de pacientes con necrosis ósea maxilar tras procedimientos 
dentales, fundamentalmente exodoncias.
El conocimiento de este posible efecto secundario de los bisfosfonatos debería ser tenido en cuenta antes de cualquier inter-
vención en este tipo de pacientes.
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surgery, chemotherapy and radiotherapy. Given the metastatic 
evolution of the disease, she started treatment with zoledronate 
(4 mg IV doses – monthly cycles). She was sent to our practice 
by her stomatologist, as she showed mandibular nonhealing soc-
kets after dental extractions, periodontal pain and paresthesia 
of the inferior dental nerve, without metastatic finding. (Figure 
3) She had been previously diagnosed and treated as having 
dental abscess. She had improved with antibiotic treatment, 
but the process had not been completely solved. Nonsurgical 
treatment was prescribed, amoxicilline and clorhexidine, and 
the lesion healed.
CASE 3
71 year old man. He had been diagnosed as having multiple 
myeloma (III-A) and treated with chemotherapy, radiotherapy 
and medullar autotransplantation. He started treatment with 
bisphosphonates due to hypercalcemia (pamidronate 90 mg 
IV doses– monthly for three years and zoledronate 4 mg IV 
doses – monthly for one year). He was sent to our practice by 
his odontologist as he showed nonhealing sockets after man-
dibular exodontics. The axial computed tomography showed 
lytic lesions and the patologic studies bone necrosis and reac-
tive osteitis. Surgical treatment was chosen, large debridement 
and a mucosal flap, complemented with antibiotic therapy and 
chlorhexidine rinses. Three weeks after surgery bone exposure 
was seen  and conservative treatment precribed, clorhexidine 
gel, with favourable evolution. 
DISCUSSION
Pamidronate and zoledronate are synthetic analogues of en-
dogenous pyrophosphate. Their clinical application involves 
a direct inhibition of the osteoclastic function.
Pamidronate disodium (Aredia®) and zoledronic acid (Zo-
meta®) belong to the aminobisphosphonate group, nitrogen 
containing bisphosphonates with greater power and slower 
INTRODUCTION
Bisphosphonates are recently acquiring increasing relevance 
with regard to the treatment of several pathologies such as lytic 
bone metastasis, malignant hypercalcemia, multiple myeloma, 
osteoporosis and Paget´s disease. (1)
These compounds are pyrophosphate analogues where a car-
bon atom has replaced the oxygen between the phosphates, 
changing the lateral chains. They show great affinity with 
hydroxyapatite crystals and inhibit bone resorption. (2)
The effectiveness and power of bisphosphonates are common 
knowledge. In general, they show high tolerance, rarely occu-
rring side effects of clinical significance. This last feature is 
caused by the accumulation of bisphosphonates on bone tissue, 
where their average life is longer than the time they spend in 
circulation. These features make bisphosphonates an effective 
and secure drug.  
In line with the increased use of these compounds, cases of 
mandibular osteonecrosis, and to a lesser extent, maxillary 
osteonecrosis, are being recorded. These cases are associated 
with treatments with certain kinds of bisphosphonates: the 
aminobisphosphonates pamidronate disodium (Aredia®) and 
zoledronic acid (Zometa®), specially in oncologic patients in 
advanced stage. R.E. Marx’s, S.L. Ruggiero’s and J.V. Bagán’s 
case reports are some of these studies. (3-6)
It is our intention to report a possible side effect produced by 
treatments with aminobisphosphonates, recently recorded in 
monographs, but of great clinical relevance due to the detriment 
in patients’ quality of life.
CASE 1
67 year-old woman; smoker (6 cigarettes / day). She had been 
diagnosed as having breast cancer (T2 N0 M0) and treated with 
surgery combined with chemotherapy and radiotherapy. Due 
to the metastatic progression of the disease, the treatment with 
bisphosphonates was initiated (pamidronate 90 mg IV doses 
– 20 monthly cycles). It is after the first 9 cycles of pamidronate 
that the patient is remitted to our practice by her oncologist, su-
ffering from burning sensation and diffuse gingival pain, regular 
gingival hemorrhages, and showing a very painful lesion (5mm 
in diameter) in the lateral edge of her right hemitongue. 
The extraction of the molar which produced the lingual sore and 
of other four teeth without viability was prescribed. Approxima-
tely one month after such exodontics, bone exposure occurred 
where the extractions had been performed. (Figure 1) Limited 
curettages of the bone necrosis were made complemented 
with antibiotic therapy (amoxicilline, clarythromycin) and 
chlorhexidine gel application. The evolution was favourable 
in every area, except in the mandibular molar one, where the 
bone exposure maintained the lingual sore, requiring a more 
aggressive debridement. Although the exposure didn’t disap-
pear completely, control of the patient’s pain was achieved with 
the resolution of the  lingual lesion. (Figure 2)
CASE 2
49 year old woman; smoker (30 cigarettes / day). She had been 
diagnosed as having breast cancer (T1 N0 M0) and treated with 
Fig. 1. Case 1. Bone necrosis one month after nonviable tooth exodontic.
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metabolization compared to those synthetized earlier. The 
use of these bisphosphonates is increasing in the treatment of 
several diseases such as hypercalcemia associated with mul-
tiple myeloma or metastatic cancer, osteoporosis and Paget’s 
disease. (1,2)
Some of the mechanisms for antiresorptive action and the 
subsequent low fragility of bone tissue are:
-Direct antiapoptotic effect on osteoblasts regardeless of the 
proapoptotic common stimulation, in vitro and in vivo. 
-Decreased osteoclast progenitor development and decreased 
mature osteoclasts recruitment in bone tissue. 
-Promotion of apoptosis of mature osteoclasts blocking regu-
lating proteins of mevalonate pathway.  (7,8)
-Antiangiogenic properties reducing the circulating endothelial 
growth factor (EGF). (5) 
Bisphosphonates have a direct effect on this dynamic unit 
which regulates the turn-over between bone formation and 
resorption, increasing osteoblasts proliferation and decrea-
sing osteoclasts average life, activity and adherence to the 
mineralized matrix. These effects have been also seen in the 
maxillofacial area. (9-11)
Through such metabolic changes, aminobisphosphonates redu-
ce bone resorption decreasing skeletal morbidity in oncological 
patients with bone metastasis. They relieve bone pain, stabilize 
or even improve lytic bone lesions, decrease the incidence of 
pathologic fractures, spinal cord compression, hypercalcemia 
and the need of palliative radiation therapy, noticeably im-
proving patients’ quality of life. The median time to the first 
skeletal event is also lengthened and the development of new 
osteolytic lesions is prevented. As a long-term effect, they also 
decrease the need of subsequent orthopedic surgery although 
they don’t lengthen survival. (12,13)
With the increasing use of pamidronate and zoledronate new 
cases of osteonecrosis are being reported, although sometimes 
there is no causal connection due to a lack of previous literature. 
(14) The three cases here described showed resistance to both 
medical and surgical treatments. They were oncological patients 
afflicted with metastatic breast cancer or multiple myeloma who 
had been treated with such drugs (Pamidronate 90 mg monthly 
IV, Zoledronate 4 mg monthly IV).   
 According to R.E. Marx, the incidence of avascular necro-
sis of the jaws induced by pamidronate and zoledronate is 
significant, especially in therapies involving corticosteroids. 
S.L. Ruggiero’s and J.V. Bagán’s cases reports are some of 
the studies which support this side effect. There is  evidence 
of exposed necrotic bone, more frequently at the mylohyoid 
ridge and at the crestal mandible. Radiographic images might 
present a normal structure without visible lesions, because the 
bone density remains, inespecific changes or lytic lesions. Risk 
seems to be increased by long term treatments (longer than a 
year), and particularly when synchronic tumors, hypoprotei-
nemia, steroids, renal failure or simultaneous chemotherapy 
treatments occur. (3-5)
At the beginning, the reported cases were diagnosed as di-
fferent dental procedures such as odontalgia, dental abscess, 
osteomyelitis, etc... and extraction of the painful dental pieces 
always resulted in a new bone exposure. This might involve 
the physician as a possible worsening factor of the process, 
making it even more complex. (6)
Mandibular-maxillary occurrence of this pathology in the cases 
treated in our department and the absence of lesions in the rest 
of the bone tissues supports R.E. Marx’s hypothesis, which 
suggests decisive influence of dental structures. (4) The bone, 
externally exposed through dental attachments, requires an 
adequate metabolism and blood supply. The normal turn-over 
modified by inhibition of osteoclastic resorption and vascular 
insufficiency could exceed bone vital capacity, resulting in avas-
cular bone necrosis (5). This osteonecrosis is difficult to treat, 
having no established guidelines for the time being. We have 
obtained successful results from the treatment of medium size 
lesions. However, complete resolution has not been achieved 
in the case of the largest one, where the treatment was merely 
palliative. Each new extraction, as well as debridements,  can 
cause a greater exposure. Direct closure over bone tissue could 
Fig. 2.   Case 1. Bone necrosis after molar extraction and lingual sore before 
debridement.
Fig. 3. Case 2. Osteonecrosis of the left jaw when the patient was sent to our 
practice.
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fail and sometimes cause worsening, because it is difficult to be 
sure that the remaining bone is healthy. Surgery was reserved 
only for the areas which caused painful lesions on the tongue 
or soft tissue — more aggressive alternatives and hyperbaric 
oxygen cannot be dismissed as a therapeutic option. (3-6,14)
From our own experience we agree with R.E. Marx that the 
antibiotic treatment (penicillin, erythromycin), together with 
limited debridements, is the best option to palliate, or even 
solve , this kind of lesions. (4,5) It is vital to maximize oral 
hygiene and the use of chlorhexidine containing gel and rinse, 
as well as the restriction of aggressive actions such as exo-
dontics, unless they are unavoidable. If surgical treatment is 
required, R.E. Marx recommends a two months interruption 
of bisphosphonates. (3)  
It is unquestionable that other well-known factors also contribu-
te to the appearance of mandibular or maxillary osteonecrosis 
(radiation therapy, chemotherapy, corticoids, infections, anemia 
and vasoconstrictor local anesthetics). (15) From them all, 
radiation therapy remains the most influential, when it is used 
in the treatment of head and neck tumors. Our department has a 
population of reference of 560,000 and started giving assistance 
over 25 years ago; the incidence of malignant tumors in this 
population approaches the European average. The appearance 
of three similar cases, the only ones in our service which are 
not associated with head and neck radiation therapy and in 
less than six months, leads us to think of the appearance of a 
new factor.    
Although a direct connection with the use of bisphosphonates 
in this pathology has not been established yet, the treatment 
with pamidronate and zoledronic acid, associated or not with 
other therapies, is common to all cases. 
Until a further knowledge about the causes for this pathology 
is achieved, the best option seems to be a maximum control of 
the cases treated with pamidronate and zoledronate.  
CONCLUSIONS
-Treatment with pamidronate and zoledronate might be a deter-
mining factor in oncological patients suffering from mandible 
and maxilla bone necrosis. 
- A surgical performance carried out by oral and maxillofacial 
surgeons, stomatologists and odontologists might lead to bone 
exposure.  
-It is a pathology difficult to treat, in patients who usually have 
a previously limited quality of life. 
-A treatment based on conservation and as harmless as possi-
ble seems to be the most advisable way of acting with these 
patients.   
-Further research will be essential to clarify the cause, minimize 
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